Last updated: March 1, 2026
What is the drug identified by NDC 70700-0182?
NDC 70700-0182 corresponds to Sotalol Hydrochloride Tablets, 80 mg. It is an antiarrhythmic medication used for the management of ventricular arrhythmias and atrial fibrillation/flutter. It is available in branded and generic forms.
Market Size and Demand Drivers
Current Sales and Market Penetration
- Estimated US sales in 2022: approximately $150 million.
- Market share: Generic sotalol accounts for over 75% of prescriptions.
- Prescriber base: cardiologists, electrophysiologists, and primary care physicians.
Drivers of Demand
- Increasing prevalence of atrial fibrillation: over 33 million cases globally.
- Rising cardiovascular disease burden in aging populations.
- Preferential use in outpatient settings due to oral administration.
- Competitive landscape features several generics, reducing prices.
Competitive Landscape
Key Players
| Manufacturer |
Product Name |
Market Share |
Pricing (Average Wholesale Price per 30 tablets) |
| Mylan Pharmaceuticals |
Sotalol Hydrochloride 80 mg |
45% |
$40 |
| Teva Pharmaceuticals |
Sotalol Hydrochloride 80 mg |
20% |
$42 |
| Other Generics |
Multiple |
30% |
$38–$45 |
| Branded (e.g., Betapace) |
Betapace Tablets |
5% |
$200+ |
Regulatory Status
- FDA Approval: Approved since 1984.
- Generic approvals: Multiple generics approved since 2005.
- Regulatory pathways favor label similarity, enabling quick market entry for generics.
Price Projections
Short-Term (Next 12 months)
- Price trend: Slight downward pressure expected due to increasing generic competition.
- Average Wholesale Price (AWP): Anticipated to remain within $38–$45 per 30 tablets.
- Market volume: Estimated to grow modestly (~3-5%) driven by rising cardiovascular cases.
Long-Term (Next 3-5 years)
- Price stabilization: Likely at current levels, barring supply chain disruptions.
- Market saturation: Approaching maturity; significant price reduction unlikely.
- Potential shifts: Introduction of biosimilar or reformulations could exert further downward pressure.
Market Risks and Opportunities
Risks
- Drug shortages: Manufacturing issues could constrain supply.
- Price erosion: Increased penetration of low-cost generics.
- Regulatory changes: New guidelines affecting preferred prescribing.
Opportunities
- Brand differentiation: Developing formulations with improved pharmacokinetics.
- Geographic expansion: Emerging markets may accept higher-priced products.
- Combination therapies: Adjunct use with other cardiovascular drugs.
Summary
The NDC 70700-0182 drug, primarily generic sotalol, holds a steady share in the antiarrhythmic market with forecasted prices remaining stable around current levels for the foreseeable future. The market faces ongoing generic competition, which constrains price growth but maintains consistent demand driven by the prevalence of arrhythmias.
Key Takeaways
- The current average wholesale price for 80 mg sotalol tablets ranges from $38 to $45.
- Overall market demand grows slowly, influenced by aging populations and increased arrhythmia prevalence.
- Market entry of generics has suppressed prices and will continue to do so.
- Long-term price projections suggest stability, with minimal risk of sharp declines absent supply chain issues or regulatory shocks.
- Opportunities exist in expanding geographic reach and developing new formulations.
FAQs
1. Why is sotalol price stability expected in the coming years?
The drug’s patent expiration and multiple generic options limit pricing power, maintaining current levels. Market saturation and predictable demand also contribute to stability.
2. Are there any recent regulatory changes affecting this drug?
No recent regulatory shifts specifically impact sotalol. FDA guidelines continue to allow approvals of generics with bioequivalence data.
3. How does the presence of multiple generics influence pricing?
Intense competition among generics keeps prices low, with no single manufacturer holding significant market dominance.
4. What are the main safety concerns with sotalol?
Risks include proarrhythmia, especially torsades de pointes, requiring careful patient monitoring and contraindication screening.
5. Which markets beyond the US show potential for growth?
Europe, Asia-Pacific, and Latin America are expanding markets, where cardiovascular disease rates are rising, and access to affordable generics is increasing.
Sources
[1] IQVIA, 2022. Pharmaceutical Market Data.
[2] FDA, 2022. Drug Approvals and Labeling Database.
[3] IMS Health, 2022. Global Prescription Data.
[4] Analyze Pharma, 2023. Market Trends Report.
